-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Parkinson's disease (PD) is a common neurological degenerative disease that is common in older people and has an average age of about 60.
of Parkinson's disease patients in our country are currently distributed cases, only a few patients have a family history.
pathological change of Parkinson's disease is the degenerative death of the meso-black dopamine-energy neurons in the central brain, which causes a significant reduction in the dabioda content of the symposome.
progress has been made in the genetic basis of familyal and exudable Parkinson's disease (PD), the biological basis and cellular context of this risk remain unclear.
From existing studies, we know that about 1-2% of PDs are associated with the classic Mendel genetic pattern, and that most diseases are driven by a complex set of factors, of which multigene risk seems to play a key role.
fact that many genes containing pathogenic mutations are also at risk sites identified by the Genome-wide Association Study (GW-AS) supports the view that both forms involve common paths.
, in single-gene and non-single-gene PD, these polygonal genes may interact to regulate common downstream targets.
In this study, the authors' team used the largest current genetic and gene expression data available from the International Parkinson's Disease Genetics Consortium (IPDGC) and the Accelerated Drug Partner Parkinson's Disease Initiative (AMP-PD) to determine the biological processes of PD using high-volume and non-hypothetical methods.
to assess the effect of common variation on Parkinson's disease risk by applying large-scale gene set-specific multigene risk scoring (PRS) analysis, with a focus on a publicly annotated gene set of representative treatment pathways.
by assessing the effects of rare mutations on the risk of Parkinson's disease in a separate set of genome-wide sequencing data, the authors found evidence of a devastating allied gene burden that is rare in a range of processes, including neuron transmission-related pathways and immune responses.
this study also explored the rich patterns associated with expressing cell specificity by using single-cell gene expression data, and proved that dopamine-energy neurons, 5-serotonin-energy neurons, hyalural brain GABA-energy neurons and neurogenic cells have significant risks.
addition, the authors' team used transcriptional group data from PD patients' blood to build a new network expression community map that revealed the rich functions of inflammatory signaling pathlines, processes associated with cell death mechanisms, and mitochondrial stabilization disorders.
Bandres-Ciga, S., Saez-Atienzar, S., Kim, J.J. et al. Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease. Acta Neuropathol 140, 341–358 (2020). MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here